阿斯利康“戈鲁利单抗”国内申报上市,自免双抗新药剑指全身型重症肌无力

摩熵医药
Dec 25, 2025

12月24日,据CDE网站显示,阿斯利康的戈鲁利单抗(gefurulimab)在国内申报上市。根据临床试验进展,推测此次申报的适应症为全身型重症肌无力(gMG)。截图来源:CDE戈鲁利单抗是一种结构紧凑的双特异抗体(约25 kDa),其设计极为精简,仅包含靶向补体C5的重链可变区与特异性结合白蛋白的抗体片段。该结构赋予其两大关键优势:较小的分子尺寸有助于提升组织渗透性,而与白蛋白的结合可显著延长其...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10